Yanhui Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yanhui Cai has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Haiyun Guo
Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
4 shared publications- Wugang Hou
Department of Anesthesiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China
4 shared publications Shiquan Wang
Department of Anaesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
3 shared publications- Hailong Dong
Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, China
2 shared publications - Haiyun Guo
Department of Anaesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China; Key Laboratory of Anaesthesiology, Fourth Military Medical University, Ministry of Education, Xi'an, Shaanxi, China
2 shared publications Huaning Wang
Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
2 shared publications
Latest Publications
- Open Access
- 9 May 2026
- Published by Elsevier in Experimental Neurology
- Vol. 403, 115816
Intraoperative cerebral blood flow threshold standardization in a mouse model of global cerebral ischemia: Parallel evaluation of laser doppler flowmetry and laser speckle contrast imaging
- 9 May 2026
- Published by Elsevier in Experimental Neurology
- Vol. 403, 115816
Open AccessIntraoperative cerebral blood flow threshold standardization in a mouse model of global cerebral ischemia: Parallel evaluation of laser doppler flowmetry and laser speckle contrast imaging
- Open Access
- 24 August 2024
- Published by Elsevier in Brain Research
- Vol. 1844, 149194
Brain glycogen: A key to revealing the pathology of mental diseases
- 24 August 2024
- Published by Elsevier in Brain Research
- Vol. 1844, 149194
Open AccessBrain glycogen: A key to revealing the pathology of mental diseases
- Open Access
- 7 June 2024
- Published by Elsevier in Redox Biology
- Vol. 74, 103234
Dysfunction of astrocytic glycophagy exacerbates reperfusion injury in ischemic stroke
- 7 June 2024
- Published by Elsevier in Redox Biology
- Vol. 74, 103234
Open AccessDysfunction of astrocytic glycophagy exacerbates reperfusion injury in ischemic stroke
- 23 December 2022
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 39 (4) , 690-694
Brain Glycogen: An Angel or a Devil for Ischemic Stroke?
- 23 December 2022
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 39 (4) , 690-694
Brain Glycogen: An Angel or a Devil for Ischemic Stroke?
- Open Access
- 13 October 2021
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 18 (1) , 1-17
Astrocytic A1/A2 paradigm participates in glycogen mobilization mediated neuroprotection on reperfusion injury after ischemic stroke
Background: Astrocytic glycogen works as an essential energy reserve for surrounding neurons and is reported to accumulate excessively during cerebral ischemia/reperfusion (I/R) injury. Our previous study found that accumulated glycogen mobilization exhibits a neuroprotective effect against I/R damage. In addition, ischemia could transform astrocytes into A1-like (toxic) and A2-like (protective) subtypes. However, the underlying mechanism behind accumulated glycogen mobilization-mediated neuroprotection in cerebral reperfusion injury and its relationship with the astrocytic A1/A2 paradigm is unknown. Methods: Astrocytic glycogen phosphorylase, the rate-limiting enzyme in glycogen mobilization, was specifically overexpressed and knocked down in mice and in cultured astrocytes. The I/R injury was imitated using a middle cerebral artery occlusion/reperfusion model in mice and an oxygen–glucose deprivation/reoxygenation model in cultured cells. Alterations in A1-like and A2-like astrocytes and the expression of phosphorylated nuclear transcription factor-κB (NF-κB) and phosphorylated signal transducer and activator of transcription 3 (STAT3) were determined by RNA sequencing, immunofluorescence and immunoblotting. Metabolites, including glycogen, NADPH, glutathione and reactive oxygen species (ROS), were analyzed by biochemical analysis. Results: Here, we observed that astrocytic glycogen mobilization inhibited A1-like astrocytes and enhanced A2-like astrocytes after reperfusion in an experimental ischemic stroke model in vivo and in vitro. In addition, glycogen mobilization could enhance the production of NADPH and glutathione by the pentose phosphate pathway (PPP) and reduce ROS levels during reperfusion. NF-κB inhibition and STAT3 activation caused by a decrease in ROS levels were responsible for glycogen mobilization-induced A1-like and A2-like astrocyte transformation after I/R. The astrocytic A1/A2 paradigm is closely correlated with glycogen mobilization-mediated neuroprotection in cerebral reperfusion injury. Conclusions: Our data suggest that ROS-mediated NF-κB inhibition and STAT3 activation are the key pathways for glycogen mobilization-induced neuroprotection and provide a promising metabolic target for brain reperfusion injury in ischemic stroke.
- 13 October 2021
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 18 (1) , 1-17
Open AccessAstrocytic A1/A2 paradigm participates in glycogen mobilization mediated neuroprotection on reperfusion injury after ischemic stroke
Background: Astrocytic glycogen works as an essential energy reserve for surrounding neurons and is reported to accumulate excessively during cerebral ischemia/reperfusion (I/R) injury. Our previous study found that accumulated glycogen mobilization exhibits a neuroprotective effect against I/R damage. In addition, ischemia could transform astrocytes into A1-like (toxic) and A2-like (protective) subtypes. However, the underlying mechanism behind accumulated glycogen mobilization-mediated neuroprotection in cerebral reperfusion injury and its relationship with the astrocytic A1/A2 paradigm is unknown. Methods: Astrocytic glycogen phosphorylase, the rate-limiting enzyme in glycogen mobilization, was specifically overexpressed and knocked down in mice and in cultured astrocytes. The I/R injury was imitated using a middle cerebral artery occlusion/reperfusion model in mice and an oxygen–glucose deprivation/reoxygenation model in cultured cells. Alterations in A1-like and A2-like astrocytes and the expression of phosphorylated nuclear transcription factor-κB (NF-κB) and phosphorylated signal transducer and activator of transcription 3 (STAT3) were determined by RNA sequencing, immunofluorescence and immunoblotting. Metabolites, including glycogen, NADPH, glutathione and reactive oxygen species (ROS), were analyzed by biochemical analysis. Results: Here, we observed that astrocytic glycogen mobilization inhibited A1-like astrocytes and enhanced A2-like astrocytes after reperfusion in an experimental ischemic stroke model in vivo and in vitro. In addition, glycogen mobilization could enhance the production of NADPH and glutathione by the pentose phosphate pathway (PPP) and reduce ROS levels during reperfusion. NF-κB inhibition and STAT3 activation caused by a decrease in ROS levels were responsible for glycogen mobilization-induced A1-like and A2-like astrocyte transformation after I/R. The astrocytic A1/A2 paradigm is closely correlated with glycogen mobilization-mediated neuroprotection in cerebral reperfusion injury. Conclusions: Our data suggest that ROS-mediated NF-κB inhibition and STAT3 activation are the key pathways for glycogen mobilization-induced neuroprotection and provide a promising metabolic target for brain reperfusion injury in ischemic stroke.
- Open Access
- 5 September 2017
- Published by Springer Nature in BMC Anesthesiology
- Vol. 17 (1) , 1-8
TREK-1 mediates isoflurane-induced cytotoxicity in astrocytes
There are growing concerns that anaesthetic exposure can cause extensive apoptotic degeneration of neurons and the impairment of normal synaptic development and remodelling. However, little attention has been paid to exploring the possible cytotoxicity of inhalation anaesthetics, such as isoflurane, in astrocytes. In this research, we determined that prolonged exposure to an inhalation anaesthetic caused cytotoxicity in astrocytes, and we identified the underlying molecular mechanism responsible for this process. Astrocytes were exposed to isoflurane, and astrocytic survival was then measured via LDH release assays, MTT assays, and TUNEL staining. TWIK-related potassium (K+) channel-1 (TREK-1) over-expression and knockdown models were also created using lentiviruses. The levels of TREK-1 and brain-derived neurotrophic factor (BDNF) were measured via Western blot and qRT-PCR. Prolonged exposure to isoflurane decreased primary astrocytic viability in a dose- and time-dependent manner. Moreover, with prolonged exposure to isoflurane, the TREK-1 level increased, and the BDNF level was reduced. TREK-1 knockdown promoted the survival of astrocytes and increased BDNF expression following isoflurane exposure. Overdoses of and prolonged exposure to isoflurane induce cytotoxicity in primary astrocytes. TREK-1 plays an important role in isoflurane-induced cultured astrocytic cytotoxicity by down-regulating the expression of BDNF.
- 5 September 2017
- Published by Springer Nature in BMC Anesthesiology
- Vol. 17 (1) , 1-8
Open AccessTREK-1 mediates isoflurane-induced cytotoxicity in astrocytes
There are growing concerns that anaesthetic exposure can cause extensive apoptotic degeneration of neurons and the impairment of normal synaptic development and remodelling. However, little attention has been paid to exploring the possible cytotoxicity of inhalation anaesthetics, such as isoflurane, in astrocytes. In this research, we determined that prolonged exposure to an inhalation anaesthetic caused cytotoxicity in astrocytes, and we identified the underlying molecular mechanism responsible for this process. Astrocytes were exposed to isoflurane, and astrocytic survival was then measured via LDH release assays, MTT assays, and TUNEL staining. TWIK-related potassium (K+) channel-1 (TREK-1) over-expression and knockdown models were also created using lentiviruses. The levels of TREK-1 and brain-derived neurotrophic factor (BDNF) were measured via Western blot and qRT-PCR. Prolonged exposure to isoflurane decreased primary astrocytic viability in a dose- and time-dependent manner. Moreover, with prolonged exposure to isoflurane, the TREK-1 level increased, and the BDNF level was reduced. TREK-1 knockdown promoted the survival of astrocytes and increased BDNF expression following isoflurane exposure. Overdoses of and prolonged exposure to isoflurane induce cytotoxicity in primary astrocytes. TREK-1 plays an important role in isoflurane-induced cultured astrocytic cytotoxicity by down-regulating the expression of BDNF.
- 1 October 2016
- Published by Elsevier in Cancer Letters
- Vol. 381 (1) , 104-112
Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells
- 1 October 2016
- Published by Elsevier in Cancer Letters
- Vol. 381 (1) , 104-112
Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells
- 1 May 2014
- Vol. 30 (3) , 197-8, 203
[Effects of the spinal cord intrathecal injected to agmatine on intrathecal morphine analgesia].
- 1 May 2014
- Vol. 30 (3) , 197-8, 203
[Effects of the spinal cord intrathecal injected to agmatine on intrathecal morphine analgesia].
- 1 January 2014
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 35 (8) , 842
Effect of agmatine on intrathecal morphine analgesia
:Objective To observe the effect of intrathecal agmatine(AG) at the spinal cord level on morphine tolerance. Methods (1) Twenty-four SD rats were divided into four groups: control group, pure intrathecal injection(i.t.) of saline(15 μL); morphine group, i.t. morphine(15 μg/15 μL); AG group, i.t. AG (12.5 μg/15 μL); and morphine+AG group, i.t. morphine (15 μg/5 μg) and AG (12.5 μg/10 μL). Rats of the four groups were injected with 0.2 mg bee venom subcutaneously in the plantar 5 min after i.t, and the numbers of spontaneous paw withdrawal reflex were recorded within 1 hour. (2) Twenty-four SD rats were divided into three groups: control group, pure intrathecal saline(15 μL); morphine tolerance group, i.t. morphine(15 μg/5 μL) twice a day for 4 consecutive days; and morphine tolerance+AG group, i.t. morphine(15 μg/5 μL)twice a day for 4 consecutive days, on the fourth day the rats also received AG(12.5 μg/10 μL). Half of the rats were examined for thermal paw withdrawal latency and mechanical withdrawal threshold after i.t, and the other half was injected with 0.2 mg bee venom subcutaneously in the plantar 10 min after last dose; the number of spontaneous paw withdrawal reflex were recorded within 1 hour. Results (1)Compared with the control group, the numbers of flinches of intrathecal morphine and AG groups were significantly reduced(PPPConclusion Intrathecal AG has synergistic effect with morphine in pain relieving, and it can also reverse the morphine tolerance induced by repeated i.t. injection.
- 1 January 2014
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 35 (8) , 842
Effect of agmatine on intrathecal morphine analgesia
:Objective To observe the effect of intrathecal agmatine(AG) at the spinal cord level on morphine tolerance. Methods (1) Twenty-four SD rats were divided into four groups: control group, pure intrathecal injection(i.t.) of saline(15 μL); morphine group, i.t. morphine(15 μg/15 μL); AG group, i.t. AG (12.5 μg/15 μL); and morphine+AG group, i.t. morphine (15 μg/5 μg) and AG (12.5 μg/10 μL). Rats of the four groups were injected with 0.2 mg bee venom subcutaneously in the plantar 5 min after i.t, and the numbers of spontaneous paw withdrawal reflex were recorded within 1 hour. (2) Twenty-four SD rats were divided into three groups: control group, pure intrathecal saline(15 μL); morphine tolerance group, i.t. morphine(15 μg/5 μL) twice a day for 4 consecutive days; and morphine tolerance+AG group, i.t. morphine(15 μg/5 μL)twice a day for 4 consecutive days, on the fourth day the rats also received AG(12.5 μg/10 μL). Half of the rats were examined for thermal paw withdrawal latency and mechanical withdrawal threshold after i.t, and the other half was injected with 0.2 mg bee venom subcutaneously in the plantar 10 min after last dose; the number of spontaneous paw withdrawal reflex were recorded within 1 hour. Results (1)Compared with the control group, the numbers of flinches of intrathecal morphine and AG groups were significantly reduced(PPPConclusion Intrathecal AG has synergistic effect with morphine in pain relieving, and it can also reverse the morphine tolerance induced by repeated i.t. injection.
- 1 April 2013
- Vol. 21 (2) , 513-6
[Progress in biochemical characteristics of hemopexin and its clinical application].
Hemopexin (HPX) is a plasma protein with the strongest binding capacity to heme and widely involved in modulation of a variety of physiological and pathological processes. The main physiological function of HPX is to bind and transport free toxic heme. Recent studies indicate that HPX also plays roles of anti-oxidant, anti-apoptosis, immune regulation and organic protection. In addition, HPX participates in regulation of cell differentiation and extracellular matrix reconstruction. In recent years, a great deal of progress has been made in studies of the mechanisms of HPX protective effects and on possible clinical application. In the past few years, especially, a number of proteomic studies have demonstrated that HPX could be served as positive molecular biomarkers for cancers of lung, liver, kidney, colon, and uterine myoma as well as osteoarthritis. In this review, recent progress in the biochemical characteristics and function of HPX and its possible clinical applications are summarized.
- 1 April 2013
- Vol. 21 (2) , 513-6
[Progress in biochemical characteristics of hemopexin and its clinical application].
Hemopexin (HPX) is a plasma protein with the strongest binding capacity to heme and widely involved in modulation of a variety of physiological and pathological processes. The main physiological function of HPX is to bind and transport free toxic heme. Recent studies indicate that HPX also plays roles of anti-oxidant, anti-apoptosis, immune regulation and organic protection. In addition, HPX participates in regulation of cell differentiation and extracellular matrix reconstruction. In recent years, a great deal of progress has been made in studies of the mechanisms of HPX protective effects and on possible clinical application. In the past few years, especially, a number of proteomic studies have demonstrated that HPX could be served as positive molecular biomarkers for cancers of lung, liver, kidney, colon, and uterine myoma as well as osteoarthritis. In this review, recent progress in the biochemical characteristics and function of HPX and its possible clinical applications are summarized.